Observational Study of Durvalumab in Patients With Non-small-cell Lung Cancer in the United Kingdom

Primary Objectives The primary study objectives, in patients with locally advanced, unresectable Stage III NSCLC treated with durvalumab as part of the UK EAP or non-EAP, are: To describe clinical outcomes To describe the patient demographic and clinical characteristics Secondary Objective 1. To describe treatment patterns of durvalumab

CODAK: A Retrospective Observational Research Study to Describe the Characteristics and Real-world Clinical Outcomes of Patients With Locally Advanced, Unresectable Stage III Non-small Cell Lung Cancer Receiving Durvalumab in the UK

This is a retrospective observational research study to describe the characteristics and real-world clinical outcomes of patients with locally advanced, unresectable Stage III non-small cell lung cancer receiving durvalumab in the United Kingdom (the CODAK study). Physicians who have treated patients who have locally advanced, unresectable Stage III NSCLC with durvalumab will be requested to recruit patients to have their clinical data abstracted from their clinical records in line with local laws. Data from this study will provide UK-specific real-world data on patients receiving durvalumab through the Early Access Programme (EAP) or post-reimbursement.

Observational Study of Durvalumab in Patients With Non-small-cell Lung Cancer in the United Kingdom

Recruitment

Summary

Participation Requirements

Description

Tracking Information